Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, USA.
Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
J Affect Disord. 2024 Dec 15;367:148-156. doi: 10.1016/j.jad.2024.08.238. Epub 2024 Sep 2.
Many patients with bipolar disorder (BD) do not respond to or have difficulties tolerating lithium and/or other mood stabilizing agents. There is a need for personalized treatments based on biomarkers in guiding treatment options. The calcium voltage-gated channel CACNA1C is a promising candidate for developing personalized treatments. CACNA1C is implicated in BD by genome-wide association studies and several lines of evidence suggest that targeting L-type calcium channels could be an effective treatment strategy. However, before such individualized treatments can be pursued, biomarkers predicting treatment response need to be developed.
As a first step in testing the hypothesis that CACNA1C genotype is associated with serum levels of CACNA1C, we conducted ELISA measures on serum samples from 100 subjects with BD and 100 control subjects.
We observed significantly higher CACNA1C (p < 0.01) protein levels in subjects with BD. The risk single nucleotide polymorpshism (SNP) (rs11062170) showed functional significance as subjects homozygous for the risk allele (CC) had significantly greater CACNA1C protein levels compared to subjects with one (p = 0.013) or no copies (p = 0.009). We observed higher somatostatin (SST) (p < 0.003) protein levels and lower levels of the clock protein aryl hydrocarbon receptor nuclear translocator-like (ARTNL) (p < 0.03) and stress signaling factor corticotrophin releasing hormone (CRH) (p < 0.001) in BD. SST and period 2 (PER2) protein levels were associated with both alcohol dependence and lithium response.
Our findings represent the first evidence for increased serum levels of CACNA1C in BD. Along with altered levels of SST, ARNTL, and CRH our findings suggest CACNA1C is associated with circadian rhythm and stress response disturbances in BD.
许多双相情感障碍(BD)患者对锂和/或其他情绪稳定剂反应不佳或难以耐受。需要基于生物标志物的个性化治疗来指导治疗选择。钙电压门控通道 CACNA1C 是开发个性化治疗的有前途的候选者。全基因组关联研究表明 CACNA1C 与 BD 有关,并且有几条证据表明,靶向 L 型钙通道可能是一种有效的治疗策略。然而,在可以进行这种个体化治疗之前,需要开发预测治疗反应的生物标志物。
作为测试 CACNA1C 基因型与 CACNA1C 血清水平相关的假设的第一步,我们对 100 名 BD 患者和 100 名对照者的血清样本进行了 ELISA 测量。
我们观察到 BD 患者的 CACNA1C 蛋白水平显着升高(p <0.01)。风险单核苷酸多态性(SNP)(rs11062170)表现出功能意义,因为风险等位基因(CC)纯合的受试者的 CACNA1C 蛋白水平显着高于具有一个(p = 0.013)或没有副本(p = 0.009)的受试者。我们观察到较高的生长抑素(SST)(p <0.003)蛋白水平和较低的时钟蛋白芳香烃受体核转位样(ARTNL)(p <0.03)和应激信号因子促肾上腺皮质激素释放激素(CRH)(p <0.001)在 BD 中。SST 和 PER2 蛋白水平与酒精依赖和锂反应均相关。
我们的研究结果代表了 BD 中 CACNA1C 血清水平升高的第一个证据。与 SST、ARTNL 和 CRH 的改变水平一样,我们的研究结果表明 CACNA1C 与 BD 中的昼夜节律和应激反应障碍有关。